A Phase 3 interventional study of MT-1186 and Placebo in ALS, sponsored by Shionogi. Terminated at 95 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria:
Exclusions Related to Primary Diagnosis
Subjects with a history of spinal surgery after the onset of ALS, such as surgery for cervical spondylosis or a herniated disc, or plans for such surgery during the study period.
Exclusions Related to Other Neurological Disorders (including, but not limited to the following)
Subjects with the possibility that the current symptoms may be symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy, cannot be ruled out.
Exclusions Related to General Health or Concomitant Conditions
Subjects with a (GFR) \< 30 mL/Min Per 1.73 m2 at screening, using the Larsson Equation.
Exclusions Related to Medications
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MT-1186
Drug: MT-1186 · Drug: Placebo
Oral edaravone
Also known as: Oral edaravone
Oral
CAFS Score at Week 48
CAFS ranks patients' clinical outcomes based on survival time and change in the ALSFRS-R score. To calculate a patient's CAFS, each patient is compared individually to all other patients in the study. The summary score for each patient is the sum of the comparisons ( 1, 0, 1) against all other patients. After that, patients' summary scores are ranked. The CAFS rank is 1-383 and a higher CAFS rank indicates a better outcome than does a lower CAFS. Since CAFS were calculated using the imputed ALSFRS-R scores with multiple imputation method, and the maximum varies for each simulation, 383 is the maximum possible value of full range for measure of dispersion.
Time frame: up to 48 Weeks
Change From Baseline in % Slow Vital Capacity (SVC) at Week 48
SVC measurements will be conducted in clinic at around the same time of day where possible with the subject in sitting upright position. Subjects should make at least 3 attempts to generate acceptable and reproducible SVC data. The highest value was selected and recorded.
Time frame: up to 48 Weeks
Change From Baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ)40 at Week 48
The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).
Time frame: up to 48 Weeks
Time to Death, Tracheostomy or Permanent Assisted Mechanical Ventilation (≥ 23 Hours/Day)
Time frame: up to 48 Weeks
Time to Death or PAMV (≥ 23 Hours/Day)
Time frame: up to 48 Weeks
Time to Death
Time frame: up to 48 Weeks
| Milestone | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| Started | 192 | 192 |
| Completed | 125 | 121 |
| Not completed | 67 | 71 |
| Withdrew: Adverse event | 10 | 14 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 20 | 21 |
| Withdrew: Study terminated by sponsor | 26 | 23 |
| Withdrew: Other | 3 | 5 |
CAFS ranks patients' clinical outcomes based on survival time and change in the ALSFRS-R score. To calculate a patient's CAFS, each patient is compared individually to all other patients in the study. The summary score for each patient is the sum of the comparisons ( 1, 0, 1) against all other patients. After that, patients' summary scores are ranked. The CAFS rank is 1-383 and a higher CAFS rank indicates a better outcome than does a lower CAFS. Since CAFS were calculated using the imputed ALSFRS-R scores with multiple imputation method, and the maximum varies for each simulation, 383 is the maximum possible value of full range for measure of dispersion.
| Units on a scale | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| CAFS Score at Week 48 | 187.2 (4 to 383) | 184.2 (1 to 383) |
SVC measurements will be conducted in clinic at around the same time of day where possible with the subject in sitting upright position. Subjects should make at least 3 attempts to generate acceptable and reproducible SVC data. The highest value was selected and recorded.
| percentage of SVC | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| Change From Baseline in % Slow Vital Capacity (SVC) at Week 48 | -26.94 ± 2.45 | -22.15 ± 2.48 |
The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions, ranging from 0 (best health as assessed by the scale) to 100 (worse health as assessed by the measure).
| Point | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| Change From Baseline in Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ)40 at Week 48 | 2.35 ± 0.25 | 1.79 ± 0.25 |
| Months | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| Time to Death, Tracheostomy or Permanent Assisted Mechanical Ventilation (≥ 23 Hours/Day) | NA (NA to NA) | NA (NA to NA) |
| Months | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| Time to Death or PAMV (≥ 23 Hours/Day) | NA (NA to NA) | NA (NA to NA) |
| Months | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| Time to Death | NA (NA to NA) | NA (NA to NA) |
Collected over Up to 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Edaravone 105 mg (Once Daily) | 9/192 (4.7%) | 52/192 (27.1%) | 118/192 (61.5%) |
| Edaravone 105mg (2 Weeks On/Off ) | 16/192 (8.3%) | 55/191 (28.8%) | 131/191 (68.6%) |
| Event | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| DysphagiaGastrointestinal disorders | 16/192 | 15/191 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 9/192 | 10/191 |
| Amyotrophic lateral sclerosisNervous system disorders | 1/192 | 5/191 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 2/192 | 5/191 |
| COVID-19Infections and infestations | 4/192 | 4/191 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/192 | 3/191 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/192 | 2/191 |
| GastrostomySurgical and medical procedures | 3/192 | 0/191 |
| Cardiac arrestCardiac disorders | 1/192 | 2/191 |
| SyncopeNervous system disorders | 1/192 | 2/191 |
| Event | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) |
|---|---|---|
| FallInjury, poisoning and procedural complications | 36/192 | 34/191 |
| ConstipationGastrointestinal disorders | 24/192 | 27/191 |
| COVID-19Infections and infestations | 24/192 | 26/191 |
| Back painMusculoskeletal and connective tissue disorders | 8/192 | 20/191 |
| DiarrhoeaGastrointestinal disorders | 20/192 | 14/191 |
| ContusionInjury, poisoning and procedural complications | 17/192 | 14/191 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 15/192 | 13/191 |
| HeadacheNervous system disorders | 15/192 | 9/191 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/192 | 11/191 |
| InsomniaPsychiatric disorders | 11/192 | 14/191 |
| Age, Customized(Participants) | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) | Total |
|---|---|---|---|
| 18-64 years | 134 | 122 | 256 |
| 65-84 years | 58 | 70 | 128 |
| Sex: Female, Male(Participants) | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) | Total |
|---|---|---|---|
| Female | 69 | 70 | 139 |
| Male | 123 | 122 | 245 |
| Ethnicity (NIH/OMB)(Participants) | Edaravone 105 mg (Once Daily) | Edaravone 105mg (2 Weeks On/Off ) | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 5 | 14 |
| Not Hispanic or Latino | 183 | 187 | 370 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2020 to primary completion in Sep 2023, 34 months.
Results were first posted in Mar 2025, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.